Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure

Toxicological Sciences

Volumn 116, Issue 1, 2010, Pages 44-57

  Wnek, Shawn M ^a   Jensen, Taylor J ^a,b   Severson, Paul L ^a   Futscher, Bernard W ^a,b   Gandolfi, A Jay ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Arsenic; Bladder cancer; Epigenetic; Monomethylarsonous acid; UROtsa

Indexed keywords

DNA; METHANEARSONIC ACID; MONOMETHYLARSONOUS ACID; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CELL ANCHORAGE; CELL GROWTH; CELL IMMORTALIZATION; CELL LINE; CHEMICAL CARCINOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EXPOSURE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SOLID TUMOR; UROTHELIUM; WESTERN BLOTTING; ANIMAL; BLADDER TUMOR; CELL TRANSFORMATION; DOSE RESPONSE; TOXICITY; TUMOR CELL LINE;

MUS;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, SCID; ORGANOMETALLIC COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 77954370016     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq106     Document Type: Article

References (70)

1. Achanzar, W. E., Brambila, E. M., Diwan, B. A., Webber, M. M., and Waalkes, M. P. (2002). Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 94, 1888-1891.
2. Aposhian, H. V., Gurzau, E. S., Le, X. C., Gurzau, A., Healy, S. M., Lu, X., Ma, M., Yip, L.i, Zakharyan, R. A., Maiorina, R. M., et al. (2000). Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13, 693-697.
3. Benbrahim-Tallaa, L., Waterland, R. A., Styblo, M., Achanzar, W. E., Webber, M. M., and Waalkes, M. P. (2005). Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol. Appl. Pharmacol. 206, 288-298.
4. Bredfeldt, T. G., Jagadish, B., Eblin, K. E., Mash, E. A., and Gandolfi, A. J. (2006). Monomethylarsonous acid induced transformation of human bladder cells. Toxicol. Appl. Pharmacol. 216, 69-79.
5. Bredfeldt, T. G., Kopplin, M. J., and Gandolfi, A. J. (2004). Effects of arsenite on UROtsa cells: low-level arsenite causes accumulation of ubiquitinated proteins that is enhanced by reduction in cellular glutathione levels. Toxicol. Appl. Pharmacol. 198, 412-418.
6. Brown, K. G., and Ross, G. L. (2002). Arsenic, drinking water, and health: a position paper of the American Council on Science and Health. Regul. Toxicol. Pharmacol. 36, 162-174.
7. Butterworth, K. T., McCarthy, H. O., Devlin, A., Ming, L., Robson, T., McKeown, S. R., and Worthington, J. (2008). Hypoxia selects for androgen independent LNCaP cells with a more malignant geno-and phenotype. Int. J. Cancer 123, 760-768.
8. Chen, C. J., Kuo, T. L., and Wu, M. M. (1988). Arsenic and cancers. Lancet 1, 414-415.
9. Chen, H., Li, S., Liu, J., Diwan, B. A., Barrett, J. C., and Waalkes, M. P. (2004). Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 25, 1779-1786.
10. Chen, S. L., Yeh, S. J., Yang, M. H., and Lin, T. H. (1995). Trace element concentration and arsenic speciation in the well water of a Taiwan area with endemic blackfoot disease. Biol. Trace Elem. Res. 48, 263-274.
11. Cleffman, G., Reuter, W. O., and Seyfert, H. M. (1979). Increase in macromolecular amounts during the cell cycle of Tetrahymena: a contribution to cell cycle control. J. Cell Sci. 37, 117-124.
12. Crawford, J. M. (2008). The origins of bladder cancer. Lab Invest. 88, 686-693.
13. Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., et al. (2001). Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2, 544-551.
14. Eblin, K. E., Bredfeldt, T. G., Buffington, S., and Gandolfi, A. J. (2007). Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. Toxicol. Sci. 95, 321-330.
15. Eblin, K. E., Bredfeldt, T. G., and Gandolfi, A. J. (2008a). Immortalized human urothelial cells as a model of arsenic-induced bladder cancer. Toxicology 248, 67-76.
16. Eblin, K. E., Hau, A. M., Jensen, T. J., Buffington, S. E., Futscher, B. W., and Gandolfi, A. J. (2008b). The role of reactive oxygen species in arsenite and monomethylarsonous acid-induced signal transduction in human bladder cells: acute studies. Toxicology 250, 47-54.
17. Eblin, K. E., Jensen, T. J., Wnek, S. M., Buffington, S. E., Futscher, B. W., and Gandolfi, A. J. (2009). Reactive oxygen species regulate properties of transformation in UROtsa cells exposed to monomethylarsonous acid by modulating MAPK signaling. Toxicology 255, 107-114.
18. Eltze, E., Wülfing, C., Von Struensee, D., Piechota, H., Buerger, H., and Hertle, L. (2005). Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int. J. Oncol. 26, 1525-1531.
19. Eschwege, P., Ferlicot, S., Droupy, S., Ba, N., Conti, M., Loric, S., Coindard, G., Denis, I., Ferretti, L., Cornelius, A., et al. (2003). A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur. Urol. 44, 435-441.
20. Fosslien, E. (2000). Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30, 3-21.
21. Gong, Z., Lu, X., Cullen, W. R., and Le, C. (2001). Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. At. Spectrom. 16, 1409-1413.
22. Habuchi, T., Luscombe, M., Elder, P. A., and Knowles, M. A. (1998). Structure and methylation-based silencing of a gene (DBCCR1) with a candidate bladder cancer tumor suppressor region at 9q32-33. Genomics 48, 277-288.
23. Habuchi, T., Takahashi, T., Kakinuma, H., Wang, L., Tsuchiya, N., Satoh, S., Akao, T., Sato, K., Ogawa, O., Knowles, M. A., et al. (2001). Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20, 531-537.
24. Izumi, H., Inoue, J., Hosoda, H., Shibata, T., Sunamori, M., Hirohashi, S., Inazawa, J., and Imoto, I. (2005). Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum. Mol. Genet. 14, 997-1007.
25. Janakiraman, V., Forrest, W. F., and Seshagiri, S. (2006). Estimation of baculovirus titer based on viable cell size. Nat Protoc. 1, 2271-2276.
26. Jensen, T. J., Novak, P., Eblin, K. E., Gandolfi, A. J., and Futscher, B. W. (2008). Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis 29, 1500-1508.
27. Jensen, T. J., Novak, P., Wnek, S. M., Gandolfi, A. J., and Futscher, B. W. (2009a). Arsenicals produce stable progressive changes in DNA methylation patterns that are linked to malignant transformation of immortalized urothelial cells. Toxicol. Appl. Pharmacol. 241, 221-229.
28. Jensen, T. J., Wozniak, R. J., Eblin, K. E., Wnek, S. M., Gandolfi, A. J., and Futscher, B. W. (2009b). Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-associated malignant transformation. Toxicol. Appl. Pharmacol. 255, 107-114.
29. Klein, R. D., Van Pelt, C. S., Sabichi, A. L., Dela Cerda, J., Fischer, S. M., Fürstenberger, G., and Müller-Decker, K. (2005). Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res. 65, 1808-1813.
30. Kligerman, A. D., Malik, S. I., and Campbell, J. A. (2010). Cytogenetic insights into DNA damage and repair of lesions induced by a monomethylated trivalent arsenical. Mutat. Res. 695, 2-8.
31. Kojima, C., Ramirez, D. C., Tokar, E. J., Himeno, S., Drobna, Z., Styblo, M., Mason, R. P., and Waalkes, M. P. (2009). Requirement of arsenic biomethylation for oxidative DNA damage. J. Natl. Cancer. Inst. 101, 1670-1681.
32. Lewis, D. R., Southwick, J. W., Ouellet-Hellstrom, R., Rench, J., and Calderon, R. L. (1999). Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 107, 359-365.
33. Liu, J., and Waalkes, M. P. (2008). Liver is a target of arsenic carcinogenesis. Toxicol. Sci. 105, 24-32.
34. Ludwig, S., Hoffmeyer, A., Goebeler, M., Kilian, K., Hafner, H., Neufeld, B., Han, J., and Rapp, U. R. (1998). The stress inducer arsenite activates mitogenactivated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J. Biol. Chem. 273, 1917-1922.
35. Mandal, B. K., Ogra, Y., and Suzuki, K. T. (2001). Identification of dimethylarsonous and monomethylarsonous acids in human urine of the arsenic-affected areas inWest Bengal, India. Chem. Res. Toxicol. 14, 371-378.
36. Millar, I. T., Heany, H., Heinehey, D. M., and Fernelius, W. C. (1960). Methyliiodoarsine. Inorg. Synth. 6, 113-115.
37. Monroe, J. G., and Cambier, J. C. (1983). Sorting of B lymphoblasts based upon cell diameter provides cell populations enriched in different stages of cell cycle. J. Immunol. Methods 63, 45-56.
38. Moore, G. E., Morgan, R. T., Quinn, L. A., and Woods, L. K. (1978). A transitional cell carcinoma cell line. In Vitro 14, 301-306.
39. Mure, K., Uddin, A. N., Lopez, L. C., Styblo, M., and Rossman, T. G. (2003). Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ. Mol. Mutagen. 41, 322-331.
40. Nesnow, S., Roop, B. C., Lambert, G., Kadiiska, M., Mason, R. P., Cullen, W. R., and Mass, M. J. (2002). DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 15, 1627-1634.
41. Nishiyama, H., Takahashi, T., Kakehi, Y., Habuchi, T., and Knowles, M. A. (1999). Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 26, 171-175.
42. National Research Council. (1999). Arsenic in Drinking Water. National Academy Press, Washington, DC.
43. National Research Council. (2001). Arsenic in Drinking Water: 2001 Update. National Academy Press, Washington, DC.
44. Novak, P., Jensen, T. J., Garbe, J. C., Sampfer, M. R., and Futscher, B. W. (2009). Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res. 69, 5251-5258.
45. Oshiro, M. M., Kim, C. J., Wozniak, R. J., Junk, D. J., Munoz-Rodrigues, J. L., Burr, J. A., Fitzgerald, M., Pawar, S. C., Cress, A. E., Domann, F. E., et al. (2005). Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer 7, 669-680.
46. Petrick, J. S., Ayala-Fierro, F., Cullen, W. R., Carter, D. E., and Aposhian, H. V. (2000). Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163, 203-207.
47. Petrick, J. S., Jagadish, B., Mash, E. A., and Aposhian, H. V. (2001). Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 14, 651-656.
48. Petzoldt, J. L., Leigh, I. M., Duffy, P. G., Sexton, C., and Masters, J. R. (1995). Immortalisation of human urothelial cells. Urol. Res. 23, 377-380.
49. Preston-Martin, S., Pike, M. C., Ross, R. K., Jones, P. A., and Henderson, B. E. (1990). Increased cell division as a cause of human cancer. Cancer Res. 50, 7412-7421.
50. R Development Core Team. (2007). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria.
51. Ristimaki, A., Nieminen, O., Saukkonen, K., Hotakainen, K., Nording, S., and Haglund, C. (2001). Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 158, 849-853.
52. Rossi, M. R., Masters, J. R., Park, S., Todd, J. H., Garrett, S. H., Sens, M. A., Somji, S., Nath, J., and Sens, D. A. (2001). The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ. Health Perspect. 109, 801-808.
53. Saiga, T., Adachi, T., Okamoto, E., and Midorikawa, O. (1981). An improved method for calculating colony formation in soft agar with special reference to malignancy. Experientia 37, 310-312.
54. Sens, D. A., Park, S., Gurel, V., Sens, M. A., Garrett, S. H., and Somji, S. (2004). Inorganic cadmium-and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol. Sci. 79, 56-63.
55. Shariat, S. F., Kim, J. H., Ayala, G. E., Kho, K., Wheeler, T. M., and Lerner, S. P. (2003). Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 169, 938-942.
56. Shirahama, T. (2000). Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin. Cancer Res. 6, 2424-2430.
57. Simeonova, P. P., Wang, S., Kashon, M. L., Kommineni, C., Crecelius, E., and Luster, M. I. (2001). Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium. Toxicol. Sci. 60, 279-284.
58. Styblo, M., Del Razo, L. M., Vega, L., Germolec, D. R., LeCluyse, E. L., Hamilton, G. A., Reed, W., Wang, C., Cullen, W. R., and Thomas, D. J. (2000). Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in human cells. Arch. Toxicol. 74, 289-299.
59. Styblo, M., Drobna, Z., Jaspers, I., Lin, S., and Thomas, D. J. (2002). The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110, 767-771.
60. Subbaramaiah, K., Zakim, D., Weksler, B. B., and Dannenberg, A. J. (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. 216, 201-210.
61. Tapio, S., and Grosche, B. (2006). Arsenic in the etiology of cancer. Mutat. Res. 612, 215-217.
62. Vahter, M. (1994). Species differences in the metabolism of arsenic compounds. Appl. Organomet. Chem. 8, 175-182.
63. Waalkes, M. P., Keefer, L. K., and Diwan, B. A. (2000). Induction of proliferative lesions of the uterus, testes, and liver in swiss mice given repeated injections of sodium arsenate: possible estrogenic mode of action. Toxicol. Appl. Pharmacol. 166, 24-35.
64. Wadhwa, P., Goswami, A. K., Joshi, K., and Sharma, S. K. (2005). Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int. Urol. Nephrol. 37, 47-53.
65. Walen, K. H. (2004). Spontaneous cell transformation: karyoplast derived from multinucleated cells produce new cell growth in senescent human epithelial cultures. In Vitro Cell Dev. Biol. Anim. 40, 150-158.
66. Wen, G., Calaf, G. M., Partridge, M. A., Echiburu-Chau, C., Zhao, Y., Huang, S., Chai, Y., Li, B., Hu, B., and Hei, T. K. (2007). Malignant (neoplastic) transformation of human small airway epithelial cells induced by arsenic. Mol. Med. 14, 2-10.
67. Wnek, S.M., Medeiros,M.K., Eblin,K. E., andGandolfi, A. J. (2009). Persistence of DNA damage following exposure of human bladder cells to chronic monomethylarsonous acid. Toxicol. Appl. Pharmacol. 241, 202-209.
68. Xie, Y., Liu, J., Benbrahim-Tallaa, L., Ward, J. M., Logsdon, D., Diwan, B. A., and Waalkes, M. P. (2007). Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology 236, 7-15.
69. Zhao, C. Q., Young, M. R., Diwan, B. A., Coogan, T. P., and Waalkes, M. P. (1997). Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U.S.A. 94, 10907-10912.
70. Zhou, X., Sun, H., Ellen, T. P., Chen, H., and Costa, M. (2008). Arsenite alters global histone H3 methylation. Carcinogenesis 29, 1831-1836.